NDAORALTABLETPriority Review
Approved
Mar 2017
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Lamivudine and zidovudine is a fixed-dose oral combination tablet containing two nucleoside reverse transcriptase inhibitors (NRTIs) used to treat HIV-1 infection. This combination therapy works by inhibiting reverse transcriptase, an enzyme essential for HIV replication, thereby reducing viral load in infected patients. The product represents a foundational antiretroviral approach, though it is typically used as part of a multi-drug regimen rather than monotherapy.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30%), indicating stable market position but limited growth opportunities for commercial team expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Career opportunities linked to this product are minimal (0 linked jobs identified), reflecting its mature market position and limited growth trajectory. Roles available would primarily involve defending market share rather than driving expansion, making this a lower-visibility assignment within a pharma organization.
Brand ManagerField Sales Representative
Worked on LAMIVUDINE AND ZIDOVUDINE at Aspen Pharmacare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.